Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report View Sample

Published: December 28, 2022 Report Code: GDGMDHC22442IDB-ST

Select Item

Zika Virus Infections Pipeline Drugs Market Report Overview

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

The Zika Virus Infections pipeline drugs market research report provides comprehensive information on the Zika Virus targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Zika Virus targeted therapeutics development with respective active and dormant or discontinued projects.

Zika Virus Infections Pipeline Drugs Market Segmentation by Target

The key targets in the Zika Virus Infections pipeline drugs market are Zika Virus Envelope Protein, Nonstructural Protein 1, Envelope Protein, Premembrane Protein, Aryl Hydrocarbon Receptor, Caspase 3, and Caspase 7 among others. Zika Virus Envelope Protein accounted for the highest number of Zika Virus Infections pipeline drugs in development in 2022.

Zika Virus Infections Pipeline Drugs Market Analysis, by Target

Zika Virus Infections Pipeline Drugs Market Analysis, by TargetFor more target insights on the Zika Virus Infections pipeline drugs market, download a free report sample

Zika Virus Infections Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Zika Virus Infections pipeline drugs market are Aryl Hydrocarbon Receptor Antagonist, Caspase 3 Inhibitor, Caspase 7 Inhibitor, Envelope Protein Inhibitor, Flavivirin Inhibitor, and Glucocorticoid Receptor Antagonist among others.

Zika Virus Infections Pipeline Drugs Market Analysis, by Mechanisms of Action

Zika Virus Infections Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more MoA insights on the Zika Virus Infections pipeline drugs market, download a free report sample

Zika Virus Infections Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Zika Virus Infections pipeline drugs market are intramuscular, oral, parenteral, subcutaneous, intravenous, intradermal, nasal, and transdermal. Intramuscular is the most preferred RoA in the Zika Virus Infections pipeline drugs market.

Zika Virus Infections Pipeline Drugs Market Analysis, by Routes of Administration

Zika Virus Infections Pipeline Drugs Market Analysis, by Routes of AdministrationFor more RoA insights on the Zika Virus Infections pipeline drugs market, download a free report sample

Zika Virus Infections Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Zika Virus Infections pipeline drugs market are small molecule, subunit vaccine, recombinant vector vaccine, vaccine, and DNA vaccine among others. Small molecule leads the pipeline drugs market in terms of molecule types.

Zika Virus Infections Pipeline Drugs Market Analysis, by Molecule Types

Zika Virus Infections Pipeline Drugs Market Analysis, by Molecule TypesTo know more about molecule types in the Zika Virus pipeline drugs market, download a free report sample

Zika Virus Infections Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Zika Virus Infections pipeline drugs market are Bharat Biotech Ltd, Emergex Vaccines Holding Ltd, Ennaid Therapeutics LLC, Excivion, Imutex Ltd, and Meletios Therapeutics SAS among others.

Zika Virus Infections Pipeline Drugs Market Analysis, by Companies

Zika Virus Infections Pipeline Drugs Market Analysis, by CompaniesTo know more about the leading Zika Virus Infections pipeline drugs market players, download a free report sample

Zika Virus Infections Pipeline Drugs Market Overview

Key Target Zika Virus Envelope Protein, Nonstructural Protein 1, Envelope Protein, Premembrane Protein, Aryl Hydrocarbon Receptor, Caspase 3, and Caspase 7
Key Mechanisms of Action Aryl Hydrocarbon Receptor Antagonist, Caspase 3 Inhibitor, Caspase 7 Inhibitor, Envelope Protein Inhibitor, Flavivirin Inhibitor, and Glucocorticoid Receptor Antagonist
Key Routes of Administration Intramuscular, Oral, Parenteral, Subcutaneous, Intravenous, Intradermal, Nasal, and Transdermal
Key Molecule Types Small Molecule, Subunit Vaccine, Recombinant Vector Vaccine, Vaccine, and DNA Vaccine
Leading Companies Bharat Biotech Ltd, Emergex Vaccines Holding Ltd, Ennaid Therapeutics LLC, Excivion, Imutex Ltd, and Meletios Therapeutics SAS

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Zika Virus (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Zika Virus (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acer Therapeutics Inc
Activirosomes Ltd
Acuitas Therapeutics Inc
Altimmune Inc
Ascendo Biotechnology Inc
Autonomous Therapeutics Inc
Bharat Biotech Ltd
BioCryst Pharmaceuticals Inc
BioNet-Asia Co Ltd
Biotron Ltd
BravoVax Co Ltd
Bugworks Research Inc
CanSino Biologics Inc
Cidara Therapeutics Inc
Ciloa
Cocrystal Pharma Inc
Codagenix Inc
Emergent BioSolutions Inc
Emergex Vaccines Holding Ltd
Enesi Pharma Ltd
Ennaid Therapeutics LLC
Enyo Pharma SA
Eurocine Vaccines AB
Excivion Ltd
Expres2ion Biotechnologies ApS
GeneOne Life Science Inc
GeoVax Labs Inc
GigaGen Inc
Greffex Inc
Hawaii Biotech Inc
Hercules Pharmaceuticals BV
IDBiologics Inc
ImmunityBio Inc
Imutex Ltd
IMV Inc
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
iosBio Pharma Ltd
Island Pharmaceuticals Ltd
Johnson & Johnson
Kamada Pharmaceuticals
KM Biologics Co Ltd
L2 Diagnostics LLC
Mabloc LLC
Macrophage Therapeutics Inc
Medigen Inc
Meletios Therapeutics SAS
Merck & Co Inc
Microbiotix Inc
Moderna Inc
Moleculin Biotech Inc
NanoViricides Inc
NightHawk Biosciences Inc
Novalex Therapeutics Inc
Ostrich Pharma USA Inc
Palisades Therapeutics
Plex Pharmaceuticals Inc
Precision Virologics Inc
ProtInhi BV
Replikins Ltd
ReVacc Biotech
Riboscience LLC
Sanofi
Sementis Ltd
Shanghai Junshi Bioscience Co Ltd
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
TenGen Biomedical Co
Theravectys SA
Tiba Biotech LLC
Touchlight Genetics Ltd
TrippBio Inc
Tychan Pte Ltd
Uvax Bio LLC
VBI Vaccines Inc
VenatoRx Pharmaceuticals Inc
Vir Biotechnology Inc
Virocovax
Xenothera SAS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Zika Virus Infections – Overview

Zika Virus Infections – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Zika Virus Infections – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Zika Virus Infections – Companies Involved in Therapeutics Development

Zika Virus Infections – Drug Profiles

Zika Virus Infections – Dormant Projects

Zika Virus Infections – Discontinued Products

Zika Virus Infections – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Infectious Disease reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Zika Virus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more